|
- Neuralink — Pioneering Brain Computer Interfaces
Creating a generalized brain interface to restore autonomy to those with unmet medical needs today and unlock human potential tomorrow
- Technology | Neuralink
Discover your future at Neuralink, where we lead the development of cutting-edge brain-computer interfaces
- Updates - Neuralink
Get the latest on neurotech directly from our experts Check out the Neuralink blog for news, insights, and behind-the-scenes looks at our work
- Two Years of Telepathy | Updates | Neuralink
Neuralink is building brain-computer interfaces (BCI) that will return autonomy to people with unmet medical needs Our first product, Telepathy, aims to enable people with paralysis to directly control computers, phones, and robotic limbs using their thoughts alone Telepathy records neural activity directly from the brain regions responsible for the muscles of the hands and arms and
- Neuralink raises $650 million Series E | Updates | Neuralink
Announcement June 2, 2025 Neuralink raises $650 million Series E This funding helps us bring our technology to more people—restoring independence for those with unmet medical needs and pushing the boundaries of what’s possible with brain interfaces
- A Year of Telepathy | Updates | Neuralink
A Year of Telepathy In January 2024, Noland became the first person to receive a Neuralink implant The implant, or Link, is our fully implantable, cosmetically-invisible, wireless brain-computer interface (BCI) designed to restore autonomy to people with paralysis
- PRIME Study Progress Update | Updates | Neuralink
In January, we conducted the first human implantation of our brain-computer interface This blog post shares a high-level snapshot of where we are as a company
- Neuralink’s First-in-Human Clinical Trial is Open for Recruitment
Announcement September 19, 2023 Neuralink’s First-in-Human Clinical Trial is Open for Recruitment We are happy to announce that we’ve received approval from the reviewing independent institutional review board and our first hospital site to begin recruitment for our first-in-human clinical trial
|
|
|